Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia

Key facts

Sponsor

Unity Health Toronto

Principal Investigator

Marie Faughnan, MD MSc FRCPC

Unity Health Toronto

Enrollment

2272 enrolled

Eligibility

All sexes

Timeline

2010 – 2025

Study locations (19)

• Barrow Neurological Institute, Phoenix, Arizona, United States
• University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
• David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California, United States
• University of California, San Francisco, San Francisco, California, United States
• UCHealth Pulmonary Vascular Disease Clinic - Anschutz Medical, Aurora, Colorado, United States
• Yale University, New Haven, Connecticut, United States
• Georgia Regents University, Augusta, Georgia, United States
• Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
• HHT Foundation International, Inc., Monkton, Maryland, United States
• Mayo Clinic, Rochester, Minnesota, United States
• Washington University School of Medicine, St Louis, Missouri, United States
• University of North Carolina at Chapel Hill, Chapel Hill, NC, North Carolina, United States
• Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
• University of Utah, Salt Lake City, Utah, United States
• University of Alberta, Edmonton, Alberta, Canada
• +4 more locations on ClinicalTrials.gov

Collaborators

National Institute of Neurological Disorders and Stroke (NINDS)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Hereditary hemorrhagic telangiectasia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07255846
  A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia
  Terremoto Biosciences Inc.
• ENROLLING BY INVITATIONNCT07445347
  Efficacy and Tolerance of Treatment With Bevacizumab for Severe Liver Involvement With High Cardiac Output in Hereditary Hemorrhagic Telangiectasia Within the French Hereditary Hemorrhagic Telangiectasia Network
  Poitiers University Hospital
• RECRUITINGPHASE1, PHASE2NCT06659640
  A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
  Alnylam Pharmaceuticals
• ACTIVE NOT RECRUITINGNCT07018401
  Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia Longitudinal Assessment Study
  Massachusetts General Hospital
• ENROLLING BY INVITATIONNCT06261333
  Quality of Life in Patients With Hemorrhagic Telangiectasia
  University Hospital, Essen
• ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT03850964
  Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)
  Cure HHT
• RECRUITINGNANCT05641142
  Prospective Study of Antiplatelet and Anticoagulation Therapy in Hereditary Haemorrhagic Telangiectasia
  University Hospital, Clermont-Ferrand
• ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05406362
  Assess Safety and Efficacy of VAD044 in HHT Patients
  Vaderis Therapeutics AG

See all trials for Hereditary hemorrhagic telangiectasia →